Johnson & Johnson (JNJ) Offering Possible 9.29% Return Over the Next 29 Calendar Days

Johnson & Johnson’s most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $140.00 short put and a strike $130.00 long put offers a potential 9.29% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $140.00 by expiration. The full premium credit of $0.85 would be kept by the premium seller. The risk of $9.15 would be incurred if the stock dropped below the $130.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 41.99 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Johnson & Johnson

Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
Tue, 15 Sep 2020 21:45:09 +0000
In the latest trading session, Johnson & Johnson (JNJ) closed at $148.89, marking a +0.36% move from the previous day.

Some volunteers quit J&J COVID-19 trial in Spain after AstraZeneca scare: investigator
Tue, 15 Sep 2020 15:44:05 +0000
Some volunteers have quit Johnson & Johnson’s COVID-19 vaccine trial in Spain after news of side effects in a participant in AstraZeneca’s trial, the Spanish programme’s lead investigator told Reuters on Tuesday. The investigator, Alberto Borobia, said there were enough reserve volunteers for the trial to continue as normal, however. “Many have called to ask us some more detail about the risk of the vaccine, whether what happened with that vaccine had anything to do with the one we are studying, these types of questions,” Borobia said.

The First Psychedelic Drug IPO Could Be Worth More Than Half A Billion Dollars
Tue, 15 Sep 2020 15:08:27 +0000
Compass Pathways expects its IPO to price at $14-$16 a share, potentially giving it a valuation of as much as $544 million.

AstraZeneca resumes COVID-19 vaccine trials in South Africa, health dept says
Tue, 15 Sep 2020 14:38:08 +0000

Some back out of J&J COVID-19 vaccine trial in Spain after AstraZeneca scare, lead investigator says
Tue, 15 Sep 2020 14:32:00 +0000
News of serious side effects in one participant of AstraZeneca’s COVID-19 vaccine trial led some volunteers in Johnson & Johnson’s vaccine trial in Spain to drop out, its lead investigator told Reuters on Tuesday. “Many have called to ask us some more detail about the risk of the vaccine, whether what happened with that vaccine had anything to do with the one we are studying, these types of questions,” Borobia said in the interview.

Be Sociable, Share!

Related Posts